JP2000506895A - 下痢治療におけるクロトリマゾールおよび関連化合物の使用 - Google Patents

下痢治療におけるクロトリマゾールおよび関連化合物の使用

Info

Publication number
JP2000506895A
JP2000506895A JP9533600A JP53360097A JP2000506895A JP 2000506895 A JP2000506895 A JP 2000506895A JP 9533600 A JP9533600 A JP 9533600A JP 53360097 A JP53360097 A JP 53360097A JP 2000506895 A JP2000506895 A JP 2000506895A
Authority
JP
Japan
Prior art keywords
group
phenyl
diarrhea
aromatic compound
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP9533600A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000506895A5 (enExample
Inventor
レンサー，ウェイン，アイ．
ブルグナラ，カルロ
アルパー，セス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of JP2000506895A publication Critical patent/JP2000506895A/ja
Publication of JP2000506895A5 publication Critical patent/JP2000506895A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/065—Diphenyl-substituted acyclic alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39508—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from milk, i.e. lactoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP9533600A 1996-03-20 1997-03-20 下痢治療におけるクロトリマゾールおよび関連化合物の使用 Pending JP2000506895A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/621,169 1996-03-20
US08/621,169 US5889038A (en) 1996-03-20 1996-03-20 Methods and products for treating diarrhea and scours: use of clotrimazole and related aromatic compounds
PCT/US1997/004244 WO1997034599A2 (en) 1996-03-20 1997-03-20 Use of clotrimazole and related compounds in the treatment of diarrhea

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008184496A Division JP2009007368A (ja) 1996-03-20 2008-07-16 下痢治療におけるクロトリマゾールおよび関連化合物の使用

Publications (2)

Publication Number Publication Date
JP2000506895A true JP2000506895A (ja) 2000-06-06
JP2000506895A5 JP2000506895A5 (enExample) 2004-12-02

Family

ID=24489031

Family Applications (2)

Application Number Title Priority Date Filing Date
JP9533600A Pending JP2000506895A (ja) 1996-03-20 1997-03-20 下痢治療におけるクロトリマゾールおよび関連化合物の使用
JP2008184496A Pending JP2009007368A (ja) 1996-03-20 2008-07-16 下痢治療におけるクロトリマゾールおよび関連化合物の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008184496A Pending JP2009007368A (ja) 1996-03-20 2008-07-16 下痢治療におけるクロトリマゾールおよび関連化合物の使用

Country Status (9)

Country Link
US (3) US5889038A (enExample)
EP (1) EP0910376B1 (enExample)
JP (2) JP2000506895A (enExample)
AT (1) ATE245981T1 (enExample)
DE (1) DE69723843T2 (enExample)
DK (1) DK0910376T3 (enExample)
ES (1) ES2199358T3 (enExample)
PT (1) PT910376E (enExample)
WO (1) WO1997034599A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010529107A (ja) * 2007-06-04 2010-08-26 ベン グリオン ユニバーシティ オブ ザ ネガフ リサーチ アンド ディベロップメント オーソリティ テロメラーゼ活性化化合物及びその使用方法
WO2021024872A1 (ja) * 2019-08-08 2021-02-11 株式会社レオロジー機能食品研究所 ストレス低下用及び／又は体重回復用経口組成物、並びにプラズマローゲン含有組成物の製造方法
JP2022518428A (ja) * 2019-01-16 2022-03-15 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア チロシンキナーゼ阻害剤誘発性下痢を治療する方法

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
BR9708230A (pt) 1996-03-20 2000-01-04 Harvard College Compostos de triaril metano, composição farmacêutica, e métodos de inibição do transporte de potássio ativado por cálcio de uma célula, para reduzir a desidrataçào de eritrócito falciforme e/ou retaradar a ocorrência de afoiçamento ou deformação de eritrócitos, e tratamento ou prevenção de doença, de inibição da proliferação celular em mamìferos, e de tratamento ou prevenção de uma desordem.
US5889038A (en) * 1996-03-20 1999-03-30 Children's Hospital Methods and products for treating diarrhea and scours: use of clotrimazole and related aromatic compounds
US6667063B2 (en) * 1998-06-10 2003-12-23 Albert Crum Nutritional or therapeutic supplement and method
ATE400551T1 (de) 2002-01-04 2008-07-15 Neurosearch As Kaliumkanal-modulatoren
WO2003080082A1 (en) * 2002-03-21 2003-10-02 Anadis Ltd Compositions containing labile bioactive materials and mammalian colostrum, methods of preparation and treatment
US10066254B2 (en) * 2002-05-20 2018-09-04 Cedars-Sinai Medical Center Diagnosis of constipation by analysis of methane concentration
EP1505989B1 (en) 2002-05-20 2011-02-23 Cedars-Sinai Medical Center Manipulation of the rate of gastrointestinal transit by modulating intestinal methane concentration
US9072728B2 (en) * 2003-09-18 2015-07-07 Children's Medical Center Corporation Treatment of severe distal colitis
US20060013890A1 (en) * 2004-06-24 2006-01-19 Green Shawn J Dairy-derived anticholesterol immunoglobulin to lower dietary cholesterol in humans
US20070087002A1 (en) * 2005-10-14 2007-04-19 Green Shawn J Anticholesterol immunoglobulin to treat lipid raft diseases
ATE494891T1 (de) 2007-08-24 2011-01-15 Neurosearch As Carbonylamino-derivate zur behandlung von entzündlicher darmerkrankung
KR101345860B1 (ko) 2011-10-25 2013-12-30 이화여자대학교 산학협력단 모다피닐 또는 이의 유도체를 포함하는 혈관질환 치료용 조성물
WO2014152754A2 (en) 2013-03-15 2014-09-25 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
US9289418B2 (en) 2013-03-15 2016-03-22 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
CN103266281B (zh) * 2013-05-24 2015-02-04 无锡鑫常钢管有限责任公司 一种超级双相不锈钢管及其生产工艺
EA201690938A1 (ru) 2013-11-05 2016-11-30 Бен-Гурион Юниверсити Оф Дзе Негев Рисерч Энд Дивелопмент Оторити Соединения для лечения диабета и осложнений, возникающих из-за этого заболевания
AU2015301596B2 (en) 2014-08-13 2020-04-16 Cedars-Sinai Medical Center Anti-methanogenic compositions and uses thereof
WO2016161085A1 (en) 2015-04-01 2016-10-06 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US307874A (en) * 1884-11-11 Bessemer converter
US3655882A (en) * 1968-08-26 1972-04-11 Staley Mfg Co A E Stable dietary supplement for new born pigs
US3965112A (en) * 1971-01-11 1976-06-22 John Wyeth & Brother Limited Imidazoline derivatives
CA1007568A (en) * 1973-12-13 1977-03-29 Michael C. Attwell Bovine immunoglobulin isolation process
US3917615A (en) * 1974-04-01 1975-11-04 Searle & Co 1,1-Diaryl-1-oxadiazol-alkylamines
US3998832A (en) * 1975-04-16 1976-12-21 G. D. Searle & Co. Anti-diarrheal compounds
US4284829A (en) * 1977-09-13 1981-08-18 Pfizer Inc. Hydroxyalkyl and oxoalkyl substituted phenols as analgesics and sedatives
US4806685A (en) 1985-08-05 1989-02-21 Gyogyszerkutato Inteezet/Pharmaceutical Research Institute 1,1,2-triphenylpropane and -propene derivatives
JPS62163662A (ja) * 1986-01-11 1987-07-20 Nippon Nousan Kogyo Kk 犬猫用ペツトフ−ド
KR970009887B1 (ko) 1987-12-24 1997-06-19 존 에이취. 뉴만 심방의 나트륨이뇨성 펩티드의 선형유사체
AU629559B2 (en) * 1988-08-04 1992-10-08 Thomas Julius Borody Oral antibody therapy for patients with lowered immune response and composition therefor
AU5254790A (en) * 1989-04-06 1990-10-11 Chugai Seiyaku Kabushiki Kaisha Process for preparing a therapeutic agent for rotavirus infection
CA2081388A1 (en) * 1990-04-09 1991-10-10 Jonah Shacknai Antidiarrheal composition and method
DE4130689A1 (de) * 1991-09-14 1993-03-18 Biotest Pharma Gmbh Verfahren zur herstellung eines leicht loeslichen getrockneten immunglobulin-praeparats aus kolostralmilch
US5430062A (en) 1992-05-21 1995-07-04 Research Corporation Technologies, Inc. Stilbene derivatives as anticancer agents
US5387600A (en) 1992-07-30 1995-02-07 Fuji Photo Film Co., Ltd. Treating arteriosclerosis using benzimidazole compositions
US5512591A (en) 1993-02-18 1996-04-30 President And Fellows Of Harvard College Treatments for diseases characterized by neovascularization
US5439086A (en) * 1993-12-10 1995-08-08 Oceaneering International, Inc. Mechanical clutch
FR2715068B1 (fr) * 1994-01-17 1996-04-19 Paul Vidal Procédé permettant de recueillir des doses de sérocolostrum bovin destinées à être administrées par voie orale à des veaux nouveau-nés ainsi que dispositif permettant la mise en Óoeuvre de ce procédé.
US5650425A (en) 1994-04-04 1997-07-22 Pharmos Corporation Permanently ionic derivatives of steroid hormones and their antagonists
WO1996001107A1 (en) 1994-07-06 1996-01-18 Bo Arne Hofmann Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses
DE69534632T2 (de) * 1994-09-16 2006-06-14 Childrens Medical Center Clotrimazol-Metaboliten bei der Behandlung von Sichelzellenkrankheit
BR9708230A (pt) 1996-03-20 2000-01-04 Harvard College Compostos de triaril metano, composição farmacêutica, e métodos de inibição do transporte de potássio ativado por cálcio de uma célula, para reduzir a desidrataçào de eritrócito falciforme e/ou retaradar a ocorrência de afoiçamento ou deformação de eritrócitos, e tratamento ou prevenção de doença, de inibição da proliferação celular em mamìferos, e de tratamento ou prevenção de uma desordem.
US5889038A (en) 1996-03-20 1999-03-30 Children's Hospital Methods and products for treating diarrhea and scours: use of clotrimazole and related aromatic compounds
EP1052990A2 (en) 1997-11-14 2000-11-22 Neurosearch A/S Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010529107A (ja) * 2007-06-04 2010-08-26 ベン グリオン ユニバーシティ オブ ザ ネガフ リサーチ アンド ディベロップメント オーソリティ テロメラーゼ活性化化合物及びその使用方法
JP2022518428A (ja) * 2019-01-16 2022-03-15 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア チロシンキナーゼ阻害剤誘発性下痢を治療する方法
US12390473B2 (en) 2019-01-16 2025-08-19 The Regents Of The University Of California Methods of treating tyrosine kinase inhibitor-induced diarrhea
WO2021024872A1 (ja) * 2019-08-08 2021-02-11 株式会社レオロジー機能食品研究所 ストレス低下用及び／又は体重回復用経口組成物、並びにプラズマローゲン含有組成物の製造方法
JP2021024833A (ja) * 2019-08-08 2021-02-22 株式会社 レオロジー機能食品研究所 ストレス低下用及び／又は体重回復用経口組成物、並びにプラズマローゲン含有組成物の製造方法

Also Published As

Publication number Publication date
US5889038A (en) 1999-03-30
WO1997034599A3 (en) 1998-02-12
DE69723843D1 (de) 2003-09-04
WO1997034599A2 (en) 1997-09-25
JP2009007368A (ja) 2009-01-15
DK0910376T3 (da) 2003-11-17
DE69723843T2 (de) 2004-03-04
US20030119784A1 (en) 2003-06-26
ATE245981T1 (de) 2003-08-15
PT910376E (pt) 2003-12-31
EP0910376A2 (en) 1999-04-28
US6495567B1 (en) 2002-12-17
EP0910376B1 (en) 2003-07-30
ES2199358T3 (es) 2004-02-16

Similar Documents

Publication Publication Date Title
JP2000506895A (ja) 下痢治療におけるクロトリマゾールおよび関連化合物の使用
Peterson et al. Role of prostaglandins and cAMP in the secretory effects of cholera toxin
Holmgren et al. Reversal of cyclic AMP-mediated intestinal secretion in mice by chlorpromazine
Regoli Neurohumoral regulation of precapillary vessels: the kallikrein-kinin system
WO2017037041A1 (en) Use of indole compounds to stimulate the immune system
Gratwohl et al. Cyclosporine toxicity in rabbits
US20120053559A1 (en) Treatment of Proliferative Diseases with Epothilone Derivatives and Radiation
JP2008526953A (ja) 炎症性疾患のプラジカンテルでの治療
US11396510B2 (en) GABAA receptor ligand
Janssen et al. Different effects of anesthetics on spontaneous leukocyte rolling in rat skin
Pruneau et al. Characterisation of bradykinin receptors from juvenile pig coronary artery
Moloo et al. Expression of resistance to isometamidium and diminazene in Trypanosoma congolense in Boran cattle infected by Glossina morsitans centralis
Furuhata et al. Histamine-releasing properties of T-3762, a novel fluoroquinolone antimicrobial agent in intravenous use. I. Effects of doses and infusion rate on blood pressure, heart rate and plasma histamine concentration
EP2036562A1 (en) A1 adenosine receptor antagonist for preventing and treating tissue injury and sepsis associated with yersinia pestis infection
US6291449B1 (en) Use of 11-phenyl-dibenzazepine compounds to treat diarrhea or scours
JP2022544718A (ja) 敗血症性心筋症を治療するための組成物および方法
Mair et al. Medical treatment of equine colic
US3737552A (en) Method of treating gonorrhea
US20070244199A1 (en) Anti-mycobacterial formulation
Loewe et al. The Prolonging Action of Penicillin by Para-Aminohippuric Acid.
US20020004519A1 (en) Method for reducing chloride secetion by intestinal epithlial cells in situ
CN116549632A (zh) 抗Lingo-1抗体Opicinumab的新用途及针对新用途的药物
D'silva Human African trypanosomiasis: future prospects for chemotherapy
POLEC et al. Protective effect of ascorbic acid, isoascorbic acid and mannitol against tetracycline-induced nephrotoxicity
Grove et al. Efficacy of albendazole against Strongyloides ratti and S. stercorolis in vitro, in mice, and in normal and immunosuppressed dogs

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040319

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080206

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080318